Bluejay Diagnostics (BJDX) AI Stock Analysis

• Market Cap: $947.36K
• Dividend Yield: N/A
• Average Volume (3M): 2.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: 81.35%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 64
• Industry: Medical - Devices
• EPS (TTM): -685.13
• Shares Outstanding: 554,012
• 10 Day Avg. Volume: 6,741,715
• 30 Day Avg. Volume: 2,268,967
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Bluejay Diagnostics is facing significant financial difficulties with no revenue generation and persistent net losses. Technical indicators also signal bearish market sentiment, with the stock trading well below major moving averages. The valuation is unappealing, with a negative P/E ratio and no dividend yield. Overall, the stock presents a high-risk profile with limited attractiveness in the current market environment.

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc. (BJDX) is a medical diagnostics company focused on developing and commercializing innovative point-of-care solutions for the healthcare industry. The company operates primarily within the biotechnology and healthcare sectors, leveraging advanced technology to enhance diagnostic testing. Its core product is the Symphony System, designed to provide rapid and accurate testing for critical care applications, allowing healthcare providers to make timely decisions and improve patient outcomes.

How the Company Makes Money

Bluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary

Bluejay Diagnostics is struggling financially with substantial net losses and negative cash flows, despite having a solid equity position and low leverage.

Income Statement

Bluejay Diagnostics has shown some revenue growth in the TTM period, achieving a Gross Profit Margin of 88.67%. However, the company is experiencing substantial net losses, with a Net Profit Margin of -592.82% and negative EBIT and EBITDA margins, indicating significant operating challenges.

Balance Sheet

The company has a strong equity base, with an Equity Ratio of 85.76%, but the Return on Equity is negative due to net losses. The Debt-to-Equity Ratio is low at 0.03, suggesting low leverage, but ongoing losses may erode equity over time.

Cash Flow

Operating and Free Cash Flows are both negative, with a significant gap between cash flows and net income, indicating liquidity challenges. The Operating Cash Flow to Net Income Ratio is 1.03, reflecting cash outflow issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.45M	0.00	249.04K	0.00	0.00	0.00
	Gross Profit
1.28M	-780.96K	48.91K	-145.72K	-157.04K	-142.97K
	EBIT
-8.07M	-10.31M	-9.32M	-3.23M	-1.20M	-1.63M
	EBITDA
-7.77M	-9.17M	-8.99M	-3.08M	-1.04M	-1.49M
	Net Income Common Stockholders
-8.59M	-9.95M	-9.23M	-3.73M	-1.13M	-757.72K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
96.01K	2.21M	10.11M	19.05M	912.36K	96.01K
	Total Assets
0.00	4.87M	13.52M	21.02M	1.52M	916.52K
	Total Debt
0.00	352.98K	492.62K	0.00	1.06M	1.07M
	Net Debt
96.01K	-1.86M	-9.62M	-19.05M	143.55K	973.28K
	Total Liabilities
0.00	1.97M	1.98M	637.16K	5.72M	3.85M
	Stockholders Equity
-464.31K	2.89M	11.54M	20.38M	-4.21M	-2.93M
Cash Flow		Free Cash Flow
-9.25M	-9.02M	-8.94M	-4.39M	-508.71K	-1.70M
	Operating Cash Flow
-8.86M	-8.31M	-7.74M	-4.37M	-508.71K	-1.69M
	Investing Cash Flow
-393.55K	-704.17K	-1.20M	-23.95K	0.00	-6.02K
	Financing Cash Flow
9.93M	1.11M	8.07K	22.53M	1.33M	1.51M

Bluejay Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 1.71 is below the 20-day moving average (MA) of 3.17, below the 50-day MA of 3.61, and below the 200-day MA of 8.10, indicating a bearish trend. The MACD of -0.55 indicates Positive momentum. The RSI at 38.25 is Neutral, neither overbought nor oversold. The STOCH value of 3.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.

Bluejay Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
TIVC	46 Neutral	$2.17M	―	-184.96%	―	-33.67%	91.72%
NAYA	39 Underperform	$1.23M	―	123.97%	―	390.03%	84.00%
HSDT	38 Underperform	$1.65M	―	-688.88%	―	-19.25%	59.74%
VTAK	34 Underperform	$2.76M	―	-101.02%	―	-4.98%	95.05%
BJDX	29 Underperform	$947.36K	―	-178.98%	―	―	81.35%